Press Release: FDA Approves Novel Monoclonal Antibody Treatment to Control Osteoarthritis Pain in Cats
First Monoclonal Antibody Drug for Use in Any Animal Species
For Immediate Release: January 13, 2022
Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.
Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain. When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.
“Treatment options for cats with osteoarthritis are very limited. Advancements in modern veterinary medicine have been instrumental in extending the lives of many animals, including cats. But with longer lives come chronic diseases, such as osteoarthritis,” said Steven M. Solomon, M.P.H., D.V.M., director of the FDA’s Center for Veterinary Medicine. “Today’s approval marks the first treatment option to help provide relief to cats that are suffering from this condition and may significantly improve their quality of life. We also hope that today’s approval of the first monoclonal antibody by the FDA for any animal species will expand research and development of other monoclonal antibody products to treat animal diseases.”
Osteoarthritis is a degenerative condition of the joints in which the normal cartilage cushion in the joints breaks down. Eventually, the bones in the joint rub against each other, causing pain, decreased joint movement, and sometimes the formation of bone spurs or other changes in and around the joint. Osteoarthritis continues to get worse over time; however, Solensia can help manage the pain associated with the condition to improve the cat’s quality of life.
Solensia is available only by prescription from a licensed veterinarian because professional expertise is required to properly diagnose pain associated with osteoarthritis in cats, administer the injection and monitor the safe use of the product, including treatment of any adverse reactions. Solensia is given through subcutaneous (under the skin) injection once a month and is dosed based on the weight of the animal.
Because of the difficulty in assessing chronic pain levels in cats, the FDA looked at whether the overall evidence supported the conclusion that Solensia was effective in controlling pain associated with osteoarthritis in cats. The effectiveness of Solensia was evaluated in two effectiveness studies using three clinical assessments that measured different aspects of pain associated with osteoarthritis in cats.
The two clinical trials were both masked, randomized, controlled field studies involving client-owned cats with clinical signs of osteoarthritis. The cats’ veterinarians assessed the cats based on orthopedic examinations before and after treatment. The owners of the cats provided baseline scores of their cats’ levels of impairment doing certain activities (such as jumping onto furniture, using the litter box or grooming), compared to the cats’ level of ability before they developed osteoarthritis. The owners then assessed their cats’ response after receiving treatment. Overall, the cats in the treatment group had better assessment scores than those in the control group.
The most common side effects seen in cats treated with Solensia included vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis and pruritus (itchy skin). These effects were relatively mild and did not require cessation of treatment.
Veterinarians should advise owners about the possible adverse events and side effects before using the drug. The FDA encourages cat owners to work with their veterinary team to report any adverse events or side effects potentially related to the use of any drug, including Solensia.
The FDA granted approval of Solensia to Zoetis Inc.
NADA 141-546 FOI Summary (fda.gov)
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Read the original press release on the FDA website: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-control-pain-cats-osteoarthritis-first-monoclonal-antibody-drug-use-any
Read more articles in the category Health and Welfare and see other Press Releases
Gifts featuring cats you know! Visit Portraits of Animals
Fine Art • Photography • Gifts • Greeting Cards • Books • Commissioned Portraits & Artwork
Great Rescues Day Book:
Portraits, Rescue Stories, Holidays and Events, Essential Feline Information, All in One Book
Each month features one of my commissioned portraits of a feline or felines and their rescue story along with a kitty quote on the left page, and on the right page the month name with enough lines for all possible dates, with standard holidays and animal-themed observances and events. Great Rescues also includes a mini cat-care book illustrated with my drawings including information on finding strays or orphaned kittens, adopting for the first time or caring for a geriatric cat, a list of household toxins and toxic plants, or helping stray and feral cats and beginning with TNR.
Each book includes also 10 sheets of my “22 Cats” decorative notepaper with a collage of all the portraits in black and white so you can make your own notes or write special notes to friends.
The portraits in this book, collected as a series, won both a Certificate of Excellence and a Muse Medallion in the 2011 Cat Writers’ Association Annual Communication Contest, as well as the 22 Cats Notepaper mentioned below.
All images and text used on this site are copyrighted to Bernadette E. Kazmarski unless otherwise noted and may not be used without my written permission, although links to your site are more than welcome and are shared. Please ask if you are interested in using and image or story in a print or internet publication. If you are interested in purchasing a print of an image or a product including it, check my animal and nature website Portraits of Animals to see if I have it available already. If you don’t find it there, visit Ordering Custom Artwork for more information on a custom greeting card, print or other item.
Subscribe to my e-newsletter
Subscribe to The Creative Cat Preview E-newsletter.
© 2022 | www.TheCreativeCat.net | Published by Bernadette E. Kazmarski
Weekly schedule of features:
Sunday: Essays, Pet Loss, Poetry, The Artist’s Life
Monday: Adoptable Cats, TNR & Shelters
Tuesday: Rescue Stories
Wednesday: Commissioned Portrait or Featured Artwork
Thursday: New Merchandise
Friday: Book Review, Health and Welfare, Advocacy
Saturday: Your Backyard Wildlife Habitat, Living Green With Pets, Creating With Cats
And sometimes, I just throw my hands in the air and have fun!
4 thoughts on “Press Release: FDA Approves Novel Monoclonal Antibody Treatment to Control Osteoarthritis Pain in Cats”
Good news indeed! …and Emmie’s picture is a beautiful memory.
I love to remember Emmy as often as possible.
Wow! I’m sharing your post on my FB page; folks need to know this.
I’m happy to see this too! Mewsette is fine with her treatments but she’s only 14 and I’d hate to see arthritis pain get her in years to come. Thanks for sharing!